SARS-CoV-2 Vaccine Development and Immune Response

The rapid emergence of SARS-CoV-2 spurred an unprecedented global effort to develop vaccines capable of preventing COVID-19 and curbing viral transmission. Early vaccine platforms harnessed traditional inactivated or protein-subunit approaches, while novel modalities—including viral vectors, messenger RNA (mRNA), DNA constructs and self-assembling nanoparticles—reached clinical evaluation within months. Central to protective efficacy is induction of potent neutralising antibodies against the viral spike glycoprotein and its receptor-binding domain (RBD), alongside robust T cell immunity that limits viral replication and promotes long-lived immunological memory. Adjuvants and delivery systems have been optimised to enhance antigen presentation, steer the balance between T helper 1 (Th1) and Th2 responses, and support germinal-centre formation for affinity-matured B cells. The evolving antigenic landscape, characterised by emergent variants with spike-protein mutations, has driven iterative vaccine redesign and booster regimens to maintain breadth and durability of protection. Global equity in vaccine access, thermostability of formulations and scalable manufacturing remain critical to achieving herd immunity and forestalling future coronavirus threats.

Research from Nature Portfolio

Innovations in nanoparticle and subunit vaccine design have delivered candidates with enhanced stability, immunogenicity and cross-variant coverage. A ferritin-based nanoparticle vaccine formulated with aluminium hydroxide elicits durable, broadly neutralising serum responses against known variants of concern and SARS-CoV-1 in non-human primates, while enabling an effective anamnestic boost one year after priming and tolerating extended storage at elevated temperatures. A full-length spike subunit vaccine stabilised in the prefusion conformation and presented on thermostable nanoparticles with a saponin-based adjuvant induces high-titre anti-spike IgG, multifunctional CD4⁺ and CD8⁺ T cell responses, follicular helper T cell engagement and germinal-centre B cell formation in both murine and primate models. Complementary work using SpyTag/SpyCatcher technology to display RBD on virus-like particles demonstrates a polyclonal neutralising antibody repertoire in small and large animal models, with thermostability and lyophilisation enabling simplified distribution without loss of immunogenicity.

SARS-CoV-2 Vaccine Development and Immune Response publication trend

The graph below shows the total number of articles in sars-cov-2 vaccine development and immune response across all publications each year (not limited to Nature Index journals).

Technical terms

Spike glycoprotein: Surface protein mediating viral entry into host cells via ACE2 binding.

Receptor-binding domain (RBD): Subunit of spike responsible for attachment to host receptor.

Adjuvant: Substance enhancing immune response to an antigen.

Neutralising antibody: Antibody that blocks infection by preventing viral entry.

Germinal centre: Lymphoid microenvironment where B cells mature and undergo affinity maturation.

Virus-like particle (VLP): Non-replicating assembly of viral proteins presenting native antigenic structure.

Anamnestic response: Rapid, amplified immune response upon re-exposure to a previously encountered antigen.

References

1. Inside-out assembly of viral antigens for the enhanced vaccination. Signal Transduction and Targeted Therapy (2023).
2. ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccines. Cell (2023).
3. In search of a pan-coronavirus vaccine: next-generation vaccine design and immune mechanisms. Cellular & Molecular Immunology (2023).
4. A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates. Nature Communications (2023).
5. A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses. Nature Communications (2021).